1月22日早间,乐普生物(02157.HK)宣布,与ArriVent BioPharma, Inc.(AVBP.O,下称ArriVent)就针对消化道癌的一款抗体偶联药物(ADC)MRG007达成全球独家许可协议。公司股价早间高开逾13%,截至发稿时,涨7.95%,报2.58港元/股。 根据协议,乐普生物授予ArriVent在大中华区(包括中国大陆、中国香港、中国澳门和中国台湾)以外地区开发、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.